Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Weber, Martin S ^a,b   Benkhoucha, Mahdia ^c,d   Lehmann Horn, Klaus ^a   Hertzenberg, Deetje ^a   Sellner, Johann ^a   Santiago Raber, Marie Laure ^c   Chofflon, Michel ^c   Hemmer, Bernhard ^a   Zamvil, Scott S ^b   Lalive, Patrice H ^c,d,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; INTERLEUKIN 10; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PERTUSSIS TOXIN; TRANSFORMING GROWTH FACTOR BETA; FOXP3 PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL MATURATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; UPREGULATION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

ANIMALIA; BACTERIA (MICROORGANISMS); BORDETELLA PERTUSSIS; MUS;

ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; PERTUSSIS TOXIN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 78651231479     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016009     Document Type: Article

References (53)

1. McFarlin DE, McFarland H (1982) Multiple sclerosis. New Engl J Med 307: 1183-1188.
2. Gilden DH (2005) Infectious causes of multiple sclerosis. Lancet Neurol 4: 195-202.
3. von Herrath MG, Fujinami RS, Whitton JL (2003) Microorganisms and autoimmunity: making the barren field fertile? Nat Rev Microbiol 1: 151-157.
4. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, et al. (1997) Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 3: 1394-1397.
5. Cermelli C, Berti R, Soldan SS, Mayne M, D'Ambrosia J M, et al. (2003) High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis 187: 1377-1387.
6. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ (2003) Crossreactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol 53: 189-197.
7. Gardell JL, Dazin P, Islar J, Menge T, Genain CP, et al. (2006) Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity. J Clin Virol 37(Suppl 1): S11-16.
8. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 5.
9. Bager P, Nielsen NM, Bihrmann K, Frisch M, Hjalgrim H, et al. (2004) Childhood infections and risk of multiple sclerosis. Brain 127: 2491-2497.
10. Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67: 652-659.
11. Burnette WN (1997) Bacterial ADP-ribosylating toxins: form, function, and recombinant vaccine development. Behring Inst Mitt. pp 434-441.
12. Falnes PO, Sandvig K (2000) Penetration of protein toxins into cells. Curr Opin Cell Biol 12: 407-413.
13. Linthicum DS (1982) Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162: 211-220.
14. Bruckener KE, el Baya A, Galla HJ, Schmidt MA (2003) Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP. J Cell Sci 116: 1837-1846.
15. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, et al. (2004) TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol 173: 7070-7077.
16. Racke MK, Hu W, Lovett-Racke AE (2005) PTX cruiser: driving autoimmunity via TLR4. Trends Immunol 26: 289-291.
17. Hou W, Wu Y, Sun S, Shi M, Sun Y, et al. (2003) Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J Immunol 170: 1728-1736.
18. He J, Gurunathan S, Iwasaki A, Ash-Shaheed B, Kelsall BL (2000) Primary role for Gi protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses. J Exp Med 191: 1605-1610.
19. Arimoto H, Tanuma N, Jee Y, Miyazawa T, Shima K, et al. (2000) Analysis of experimental autoimmune encephalomyelitis induced in F344 rats by pertussis toxin administration. J Neuroimmunol 104: 15-21.
20. Cassan C, Piaggio E, Zappulla JP, Mars LT, Couturier N, et al. (2006) Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J Immunol 177: 1552-1560.
21. Chen X, Winkler-Pickett RT, Carbonetti NH, Ortaldo JR, Oppenheim JJ, et al. (2006) Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol 36: 671-680.
22. Chen X, Howard OM, Oppenheim JJ (2007) Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol 178: 6123-6129.
23. Hofstetter HH, Grau C, Buttmann M, Forsthuber TG, Gaupp S, et al. (2007) The PLPp-specific T-cell population promoted by pertussis toxin is characterized by high frequencies of IL-17-producing cells. Cytokine 40: 35-43.
24. Lehmann D, Ben-Nun A (1992) Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J Autoimmun 5: 675-690.
25. Robbinson D, Cockle S, Singh B, Strejan GH (1996) Native, but not genetically inactivated, pertussis toxin protects mice against experimental allergic encephalomyelitis. Cell Immunol 168: 165-173.
26. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, et al. (2003) Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197: 1073-1081.
27. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
28. Munoz JJ, Bernard CC, Mackay IR (1984) Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell Immunol 83: 92-100.
29. Brocke S, Gaur A, Piercy C, Gautam A, Gijbels K, et al. (1993) Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365: 642-644.
30. Schiffenbauer J, Johnson HM, Butfiloski E, Wegrzyn L, Soos JM (1993) Staphylococcal enterotoxins reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci 90: 8543-8546.
31. Soos JM, Schiffenbauer J, Johnson HM (1993) Treatment of PL/J mice with the superantigen, staphycoccal enterotoxin B, prevents development of experimental allergic encephalomyelitis. J Neuroimmunol 43: 39-43.
32. Su SB, Silver PB, Zhang M, Chan CC, Caspi RR (2001) Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals. J Immunol 167: 250-256.
33. Agarwal RK, Sun SH, Su SB, Chan CC, Caspi RR (2002) Pertussis toxin alters the innate and the adaptive immune responses in a pertussis-dependent model of autoimmunity. J Neuroimmunol 129: 133-140.
34. Andreasen C, Powell DA, Carbonetti NH (2009) Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One 4: e7079.
35. Lenardo MJ (1991) Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353: 858-861.
36. Radvanyi LG, Mills GB, Miller RG (1993) Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. J Immunol 150: 5704-5715.
37. Wesselborg S, Janssen O, Kabelitz D (1993) Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150: 4338-4345.
38. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21: 305-334.
39. Ben-Nun A, Mendel I, Sappler G, Kerlero de Rosbo N (1995) A 12-kDa protein of Mycobacterium tuberculosis protects mice against experimental autoimmune encephalomyelitis. Protection in the absence of shared T cell epitopes with encephalitogenic proteins. J Immunol 154: 2939-2948.
40. Zhang X, Koldzic DN, Izikson L, Reddy J, Nazareno RF, et al. (2004) IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol 16: 249-256.
41. Auffray C, Sieweke MH, Geissmann F (2009) Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27: 669-692.
42. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13: 935-943.
43. Mahnke K, Bedke T, Enk AH (2007) Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 250: 1-13.
44. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979.
45. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, et al. (2002) Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest 109: 131-140.
46. Hong J, Li N, Zhang X, Zheng B, Zhang JZ (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 102: 6449-6454.
47. O'Connor RA, Anderton SM (2008) Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol 193: 1-11.
48. Kohm AP, Carpentier PA, Anger HA, Miller SD (2002) Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 169: 4712-4716.
49. Reddy J, Illes Z, Zhang X, Encinas J, Pyrdol J, et al. (2004) Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 101: 15434-15439.
50. Stephens LA, Gray D, Anderton SM (2005) CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci U S A 102: 17418-17423.
51. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, et al. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cellinduced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A 106: 4355-4359.
52. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116: 1037-1044.
53. Kuchroo VK, Prabhu Das M, Brown JA, Ranger AM, Zamvil SS, et al. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718.